

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

BUDESONIDE ORODISPERSIBLE TABLET (JORVEZA®) FOR INDUCING REMISSION OF EOSINOPHILIC OESOPHAGITIS NICE TA708, JUNE 2021

RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
BUDESONIDE ORODISPERSIBLE TABLET (Jorveza®)	Budesonide is a non-halogenated glucocorticosteroid, which acts primarily anti-inflammatory via binding to the glucocorticoid receptor.	Treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age)	Final	NICE TA708 – recommended

MSEMOC recommendation:

Budesonide orodispersible tablet (Jorveza®) is recommended as an option for inducing remission of eosinophilic oesophagitis in adults, in accordance with NICE technology appraisal recommendations.

[NICE TA708](#) recommendation:

1.1 Budesonide as an orodispersible tablet (ODT) is recommended as an option for inducing remission of eosinophilic oesophagitis in adults.

1.2 This recommendation is not intended to affect treatment with budesonide ODT that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

For further information refer to the [Summary of Product Characteristics for Jorveza®](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis: https://www.nice.org.uk/guidance/ta708
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC
Date Approved	October 2021
Review Date	October 2026 or sooner if subject to any new updates nationally